首页> 外文期刊>海南医科大学学报(英文版) >Changes of serum tumor markers, immunoglobulins, TNF-α and hs-CRP levels in patients with breast cancer and its clinical significance
【24h】

Changes of serum tumor markers, immunoglobulins, TNF-α and hs-CRP levels in patients with breast cancer and its clinical significance

机译:乳腺癌患者血清肿瘤标志物,免疫球蛋白,TNF-α和hs-CRP水平的变化及其临床意义

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To study the serum tumor markers, immunoglobulin, TNF-α and hs-CRP in breast cancer in different pathological stages of the concentration, and to analyze the clinical significance of early diagnosis of breast cancer. Methods: A total of 130 patients with breast cancer were divided into stage I, II, III and IV according to clinical pathology. In addition, 40 patients with benign breast disease and 35 healthy subjects were selected as benign breast disease group and control group. Serum tumor markers, immunoglobulins, TNF-αand hs-CRP concentrations were measured and compared of all subjects. Results: There were no significant difference in serum tumor markers, immunoglobulin and inflammatory factors between the control group and the benign breast cancer group. The level of serum tumor markers in breast cancer group was significantly higher than that in control group and benign breast cancer group. The levels of serum CA125, CA153 and CEA were gradually increased with the severity enhancing from stage I and IV of breast cancer, and he difference was statistically significant. The level of serum immunoglobulin in breast cancer group was significantly higher than that in control group and benign breast cancer group. The levels of serum IgG and IgM increased gradually severity enhancing from stage I and IV of breast cancer, and the difference was statistically significant. The level of serum TNF-α and hs-CRP in serum of breast cancer group was significantly higher than that of control group and benign breast cancer group. The serum levels of TNF-α and hs-CRP increased gradually with severity enhancing from stage I and IV of breast cancer, and the difference was statistically significant. Conclusion: The level of serum tumor markers in breast cancer patients is increasing. Humoral and inflammatory responses are activated to varying degrees and increase with the aggregation of disease. They may involve regulating the occurrence and metastasis of breast cancer and regulating the pathophysiological function of patients. Which may be a certain clinical significance for the early diagnosis of breast cancer and disease progression.
机译:目的:以浓度的不同病理阶段研究血清肿瘤标志物,免疫球蛋白,TNF-α和HS-CRP,分析乳腺癌早期诊断的临床意义。方法:根据临床病理学,共分为II,II,III和IV阶段的130例乳腺癌患者。此外,40例良性乳腺疾病和35名健康受试者被选为良性乳腺疾病组和对照组。测定血清肿瘤标志物,免疫球蛋白,TNF-α和HS-CRP浓度,并将其与所有受试者相比。结果:对照组和良性乳腺癌组之间的血清肿瘤标志物,免疫球蛋白和炎症因子没有显着差异。乳腺癌组血清肿瘤标志物的水平显着高于对照组和良性乳腺癌组。随着乳腺癌第I和IV阶段的严重程度逐渐增加,血清Ca125,Ca153和CEA的水平,他的差异是统计学意义。乳腺癌组中血清免疫球蛋白的水平显着高于对照组和良性乳腺癌组。血清IgG和IgM的水平增加了乳腺癌第I和IV阶段的逐步严重程度,差异有统计学意义。乳腺癌组血清血清TNF-α和HS-CRP水平明显高于对照组和良性乳腺癌组。 TNF-α和HS-CRP的血清水平随着乳腺癌第I和IV阶段的严重程度而逐渐增加,差异是统计学意义。结论:乳腺癌患者血清肿瘤标志物的水平越来越多。体液和炎症反应被激活到不同程度的变化,随着疾病的聚集而增加。它们可能涉及调节乳腺癌的发生和转移,并调节患者的病理生理功能。这对于早期诊断乳腺癌和疾病进展可能是一定的临床意义。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2017年第20期|89-92|共4页
  • 作者单位

    Department of Clinical Laboratory, Jiangbei Hospital (Nanjing Dachang Hospital), Zhongda Hospital Affiliated to Southeast University, Jiangsu, Nanjing 210044, China;

    Surgery Department, Jiangbei Hospital (Nanjing Dachang Hospital), Zhongda Hospital Affiliated to Southeast University, Jiangsu, Nanjing 210044, China;

    Department of Clinical Laboratory, Jiangbei Hospital (Nanjing Dachang Hospital), Zhongda Hospital Affiliated to Southeast University, Jiangsu, Nanjing 210044, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号